Aims: We have previously demonstrated that blockade of T-type calcium channels by the nonselective antagonist, ethosuximide (ETX), is effective at reducing electrographical and behavioral correlates of alcohol-withdrawal (WD) seizure. Here, we investigated whether blockade of these calcium channels with the selective antagonist TTA-P2 also reduces alcohol-WD seizure. Short summary: The non-specific T-type calcium channel antagonist, ETX, is protective against alcohol-WD seizure. However, the mechanism of this effect is unclear. Here, we provide evidence that further suggests selective blockade of T-type calcium channels are protective against alcohol-WD seizure and WD-related mortality. Methods: We used an intermittent ethanol exposure model to produce WD-induced hyperexcitability in DBA/2 J mice. Seizure severity was intensified with the chemoconvulsant pentylenetetrazole (PTZ). Results: TTA-P2 (10 mg/kg) reduced seizure severity in mice undergoing alcohol WD with concurrent PTZ treatment (20 mg/kg). Moreover, TTA-P2 (20 and 40 mg/kg) was also protective against PTZ-induced (40 mg/kg) seizure and mortality. Conclusions: These results are consistent with prior results using ETX, and suggest that the protective effects of ETX and TTA-P2 against EtOH WD seizures are mediated by T-type calcium channels.
INTRODUCTION
Alcohol use depresses the central nervous system, and during withdrawal (WD), can result in rebound hyperexcitability whereby excitatory neural mechanisms compensate for the inhibitory effects that were exerted by chronic alcohol consumption (Saitz, 1998) . These compensatory excitatory mechanisms create an imbalance in normal levels of neural excitation and inhibition and can persist throughout the detoxification period. Symptoms of alcohol detoxification and WD include anxiety, delirium tremens, insomnia and seizures. Alcohol WD seizures are particularly dangerous, in part because the risk of seizures increases with each successive WD period (Brown et al., 1988; Becker, 1998) .
Benzodiazepines, such as lorazepam, are typically the first-line treatment for alcohol-WD (Ait-Daoud et al., 2006) . However, some recent findings suggest that they may not be the safest option for treating alcohol WD. For example, benzodiazepines can have a high potential for abuse (Morris and Victor, 1987) and have also been shown to produce rebound hyperexcitability during untreated WD periods (Morris and Victor, 1987; Becker and Veatch, 2002; Veatch and Becker, 2005) . Benzodiazepines may actually promote rebound neural excitability and possess significant abuse potential on their own, spurring efforts to identify other neural targets for potential therapeutics (Malcolm et al., 2001; Maldonado, 2017) . Moreover, treatment with anticonvulsants has been shown to be more effective at treating rebound alcohol-WD symptoms and reducing relapse behaviors than benzodiazepines (Malcolm et al., 2002) .
Multiple compensatory mechanisms may occur following the cessation of the central nervous system depressant effects of ethanol, including alterations in GABA A and NMDA receptors (Rogawski, 2005) . An additional compensatory effect of alcohol cessation is an alteration in low-voltage activated T-type calcium channels (T-channels; Mu et al., 2003; Carden et al., 2006; Graef et al., 2011) . T-channels are distributed heterogeneously throughout the brain and exist as three functionally distinct isoforms: Ca V 3.1, Ca V 3.2, and Ca V 3.3 (Talley et al., 1999; Perez-Reyes, 2003) . Acute alcohol inhibits one isoform of this channel, CaV3.2, through a PKCdependent mechanism in HEK cells and DRG neurons (Shan et al., 2013) . Furthermore, T-current is reduced in non-human primate thalamic neurons following chronic alcohol consumption (Carden et al., 2006) . WD from ethanol has been shown to increase expression and function of T-channels (Nordskog et al., 2006; Graef et al., 2011) . More specifically, Graef et al. (2011) found that Ca V 3.2 and Ca V 3.3 mRNA was increased in the thalamus during WD from chronic-intermittent alcohol exposure, and that alcohol WD shifted the steady-state inactivation curves to a more depolarized potential in thalamic reuniens neurons. One potential result of this WDinduced curve shift is to increase window currents and overall excitability in neurons rich in T-channels. Rhythmic activity in the thalamus is highly dependent on T-current (Huguenard and Prince, 1992; Huguenard, 1999) , and alterations in thalamic ictal activity has been shown to precede aberrant EEG recordings from the cortex, hippocampus and medial thalamus during alcohol-WD seizures (Walker and Zornetzer, 1974) . Activation of T-channels permits Ca2+ entry in cells, and ultimately, the low-threshold Ca2+ spike can subsequently lead to a burst of Na+-dependent action potentials (Perez-Reyes, 2003) .
These findings led us to evaluate ethosuximide (ETX; a nonspecific T-channel antagonist) as a potential therapeutic for alcohol WD. ETX was found to restore patterns of sleep activity that had been disrupted in mice undergoing alcohol WD (Wiggins et al., 2013) . We also found that mice undergoing alcohol WD have an increased number of spike-and-wave discharge events that are dosedependently reduced by ETX administration (Riegle et al., 2014) . ETX treatment also reduced the number of handling-inducedconvulsions, tonic-clonic seizures, and seizure-induced mortality in mice undergoing alcohol WD (Riegle et al., 2014 (Riegle et al., , 2015 . ETX, unlike benzodiazepines, has an additional benefit of being free of rebound hyperexcitability. Taken together, these data suggest that ETX may be an effective treatment for alcohol WD (Riegle et al., 2015) .
One caveat to the efficacy of ETX is that it may have off-target effects, and it is unclear whether the therapeutic effects of ETX are due to its blockade of T-channels or to another action of the drug. In addition to blocking T-channels, it has been proposed that ETX may also inhibit G-protein activated inwardly rectifying K + (GIRK) channels (Kobayashi et al., 2009) , sodium current (Leresche et al., 1998; Broicher et al., 2007) , and that it increases the release of GABA (Lin-Michell et al., 1986; Ponnusamy and Pradhan, 2006; Greenhill et al., 2012) . In order to determine whether blockade of T-channels are responsible for the reduction in seizure-like activity during alcohol WD (Riegle et al., 2014 (Riegle et al., , 2015 , we used the selective T-channel antagonist TTA-P2 in a model of alcohol WD-induced tonic-clonic seizure. This novel piperidine-based molecule has been shown exert a potent and reversible inhibition of recombinant T-type, but not high voltage activated, Ca 2+ channels (Shipe et al., 2008; Dreyfus et al., 2010; Choe et al., 2011) . Furthermore, TTA-P2, as well as ETX, was recently reported to reduce markers of seizure susceptibility that were induced by a Ca V 3.2 channel mutation (Eckle et al., 2014) . If the therapeutic effects of ETX during alcohol WD are due to the actions of ETX at T-channels, then blocking T-channels with the specific antagonist TTA-P2 should yield similar results. Moreover, if the deleterious effects of WD are due in part to T-channel gain of function, then selective blockade should ameliorate these effects. Here, we test whether TTA-P2 effectively reduces seizure and seizure-induced mortality in animals undergoing alcohol WD.
MATERIALS AND METHODS
All experiments were approved by the Institutional Animal Care and Use Committee of Wake Forest University. Experiments were conducted in agreement with the National Institutes of Health and the US Department of Agriculture guidelines, including procedures that reduce animal use and mitigate pain and suffering.
Intermittent alcohol exposure
Adult male DBA/2 J mice (Jackson Labs, Bar Harbor, ME) were used for these experiments. All animals were group housed, maintained on a 12 h light:dark cycle and allowed ad libitum access to standard food and water. Following 1 week habituation to the animal facility, mice were exposed to one 4-day cycle of intermittent alcohol exposure (Becker and Hale, 1993) . For each alcohol exposure period, mice were placed in a Plexiglass vapor chamber. Ethanol (95%) was volatized and delivered to the chamber by an air pump for 16 h (5:00PM until 9:00AM). All mice were subcutaneously treated with pyrazole (100 mg/kg; Sigma Aldrich, St Louis, MO), an alcohol dehydrogenase inhibitor, at the start of each exposure. Pyrazole was dissolved in saline and made fresh daily. Following each exposure period, 5 μl of tail blood was collected from each mouse and immediately placed in trichloroacetic acid (6.25% w/v). Samples were then analyzed using an NAD-ADH assay for blood ethanol concentration (BEC; Carolina Liquid Chemistries, WinstonSalem, NC). Over the four WD periods, BEC levels were 259.46 ± 7.3 mg/dl.
Drug preparation
Prior to behavioral testing, TTA-P2 was dissolved in DMSO to a concentration of 50 mM and stored at −32°C until use. On the day of behavioral testing, the stock solution was further diluted with saline to the appropriate concentration (1, 2 or 4 mg/ml) and kept at room temperature until the time of injections. PTZ was dissolved in saline to a final concentration of 2 or 4 mg/ml immediately prior to use. Injection volumes corresponded to the weight of the animal (e.g. a 25-g mouse received an injection volume of 0.25 ml).
Drug treatment
Approximately 6 h into the 4th WD period, mice were treated with the T-channel antagonist TTA-P2 (10, 20 or 40 mg/kg intraperitoneal; Alomone Labs, Jerusalem, Israel) or saline. Mice were left undisturbed in the behavioral testing facility for 30 minutes. At this time, all mice were injected with pentylenetetrazole (PTZ; 20 mg/kg (for the seizure susceptibility experiment) or 40 mg/kg (for the mortality experiment), intraperitoneal; Sigma Aldrich, St Louis, MO).
Behavioral testing: seizure susceptibility
Immediately following treatment with PTZ (20 mg/kg) mice were placed in a behavioral testing apparatus and video recorded and monitored for seizure activity for 30 min as described previously (Riegle et al., 2015) . A blind reviewer analyzed the seizure activity and scored the seizures based on the following criteria: 0, no seizure activity; 1, tail twitching and/or head nodding; 2, myoclonic activity or tonus; 3, tonic-clonic convulsion; 4, severe tonic-clonic seizure resulting in death. Mice that did not have a tonic-clonic seizure were assigned a latency of 1800s for latency to tonic-clonic seizure.
Behavioral testing
Seizure threshold and mortality Immediately following treatment with PTZ (40 mg/kg), mice were placed in a behavioral testing apparatus and video recorded and monitored for seizure activity for 30 minutes as described previously (Riegle et al., 2015) . A blind reviewer analyzed the dependent measures: overall mortality rate, latency to tonic-clonic seizure and latency to death. Mice that did not have tonic-clonic seizures or did not die were assigned latency values of 3600 s.
Statistical analyses
All data were analyzed using GraphPad Prism version 6.07 for Windows (GraphPad Software, La Jolla, CA). Seizure activity was analyzed using a two-tailed non-parametric Mann-Whitney test. Mortality rate was analyzed using a Chi-square test. Latency to tonic-clonic seizure and latency to death were analyzed with an ordinary one-way ANOVA. Post hoc testing was preformed where appropriate.
RESULTS

Experiment 1: seizure activity
In the first experiment, we assessed the ability of TTA-P2 (10 mg/kg) to protect against seizure activity induced by PTZ (20 mg/kg). These data are depicted in Fig. 1 . Mice undergoing alcohol WD demonstrated significantly lower seizure scores when pretreated with TTA-P2 compared to saline (P = 0.002; mean ± SEM for the saline group = 2.500 ± 0.1890, n = 8; mean ± SEM for the TTA-P2 group = 0.7778 ± 0.3130, n = 9).
Experiment 2: seizure threshold and mortality
To determine whether blocking T-channels would be protective against PTZ-induced seizure and mortality, we pretreated mice with 0, 10, 20 or 40 mg/kg TTA-P2. Thirty minutes later all mice were treated with a high dose of PTZ (40 mg/kg). These results are summarized in Table 1 . There was a significant effect on latency to seizure ( Fig. 2 ; P < 0.0001; F(3, 37) = 16.29) and Fisher's LSD multiple comparison test revealed that mice pretreated with 20 mg/kg TTA-P2 demonstrated longer latencies to seizure than controls (P < 0.05, t = 2.146), and mice pretreated with 40 mg/kg demonstrated longer latencies to seizure than the saline, 10, or 20 mg/kg groups (ps < 0.0001, ts > 4.455).
A Chi-square test revealed that significantly fewer mice died from PTZ-induced seizure when they were pretreated with TTA-P2 (P < 0.05). Individual chi-square tests showed that both the 20 mg/kg and the 40 mg/kg doses of TTA-P2 were protective against seizure-induced mortality compared to the saline-treated mice ( Fig. 3a; ps < 0.05). We observed that each death followed a severe tonic-clonic seizure.
There was also a significant effect on latency to death (Fig. 3b) ; P < 0.001; F(3, 37) = 7.122. A Fisher's LSD multiple comparison test confirmed that the mice pretreated with 20 mg/kg TTA-P2 had longer latencies to death compared with controls (P < 0.05, t = 2.293). Additionally, mice pretreated with 40 mg/kg TTA-P2 had longer latencies to death than the saline, 10, or 20 mg/kg groups (ps < 0.05, ts > 2.134). In summary, the T-type channel antagonist dose-dependently reduced the rate of mortality, and it delayed death in the animals that died.
DISCUSSION
Alcohol WD can result in a persistent hyperexcitable neural state that can manifest as alcohol-WD seizure. Benzodiazepines are typically the first-line treatment for alcohol WD, but, due to their addiction potential and rebound hyperexcitability, present unique challenges in a clinical setting (Morris and Victor, 1987; Becker and Veatch, 2002; Veatch and Becker, 2005; Ait-Daoud et al., 2006) . Our lab has identified T-type Ca 2+ channels as potential contributors to the hyperexcitable state observed during alcohol WD (Graef et al., 2011; Wiggins et al., 2013) . We have also successfully demonstrated that blocking T-channels with ETX dramatically reduces behavioral and electrographical correlates of alcohol-WD seizure, including seizure-induced mortality (Riegle et al., 2014 (Riegle et al., , 2015 . While these experiments support ETX as a potential therapeutic drug in treating alcohol-WD seizure, it is important to address the possibility that ETX might be exerting its anti-seizure effects through off-target drug actions. Some of these effects include the inhibition of GIRK channels (Kobayashi et al., 2009) , which may indirectly modulate T-current (Crunelli and Leresche, 1991) , inhibition of sodium current (Leresche et al., 1998; Broicher et al., 2007) , Ca 2+ -activated K + current (Leresche et al., 1998; Crunelli and Leresche, 2002) as well as an increase in GABA release (Lin-Michell et al., 1986; Ponnusamy and Pradhan, 2006; Greenhill et al., 2012) . In order to understand the mechanism by which ETX exerts anticonvulsive effects, we used a specific T-channel blocker, TTA-P2, to probe the alcohol-induced hyperexcitable state in DBA-2J mice. Specifically, we pretreated alcohol-WD mice with TTA-P2 and assessed hyperexcitability with the same measures used previously (Riegle et al., 2014 (Riegle et al., , 2015 . The data presented here show that TTA-P2 is also dose-dependently protective against alcohol WD-induced hyperexcitability and death.
In our first experiment, mice undergoing alcohol WD were pretreated with TTA-P2 followed by 20 mg/kg PTZ. This dose was chosen because it is a subthreshold dose of PTZ that will induce a tonic-clonic seizure in mice undergoing alcohol WD but not cause a behavioral seizure in alcohol-naïve mice (Riegle et al., 2015) . Here, in mice undergoing alcohol WD, 10 mg/kg TTA-P2 was protective against seizure caused by PTZ, as measured by a lower seizure score (Fig. 1) . Furthermore, three out of the nine mice pretreated with TTA-P2 did not show any seizure activity at all (a seizure score of 0), whereas all of the saline-pretreated mice demonstrated seizure activity.
In our second experiment, we pretreated mice undergoing alcohol WD with one of four doses of TTA-P2 and then treated all mice with 40 mg/kg PTZ. This dose of PTZ is lethal in mice undergoing alcohol WD, but not lethal in alcohol-naïve mice (Riegle et al., 2015) . Pretreatment with TTA-P2 dose-dependently reduced seizure and seizure-induced mortality in these mice. Specifically, both the 20 and the 40 mg/kg dose of TTA-P2, but not 10 mg/kg, significantly reduced mortality compared with saline-pretreated mice. Furthermore, the mice pretreated with 40 mg/kg TTA-P2 showed significantly longer latencies to seizure as well as significantly longer latencies to death (Fig. 2a-c) . It should be noted here that the animals that were treated with 40 mg/kg TTA-P2 were behaviorally depressed compared to saline and lower doses of TTA-P2, but this behavior appeared to be unrelated to seizure.
The studies described here strongly implicate T-channels in the development of alcohol WD-related hyperexcitability and seizure in this animal model. There are three isoforms of T-channels: Ca V 3.1, 3.2 and 3.3. Of these, Ca V 3.2 has been most associated with ethanol and ethanol WD-induced changes. TTA-P2 antagonizes all three isoforms, making it impossible to specify from these experiements which of the three plays a larger role in alcohol-WD seizure.
However, previous research has demonstrated that Ca V 3.2 mRNA is upregulated during alcohol WD with a resulting gain of function (Graef et al., 2011) , so this isoform would be a potential candidate. At this time, however, a selective Ca V 3.2 antagonist does not exist.
Until recently, it was difficult to selectively block T-channels, as many of the pharmacological agents available have potential offtarget effects (e.g. ETX). TTA-P2 is a novel compound that has previously been shown to selectively block T-current in neuronal and DRG cells (Shipe et al., 2008; Dreyfus et al., 2010; Choe et al., 2011) . The current study utilized moderate-to high drug doses, and it is important to consider potential off-target effects of TTA-P2. Shipe et al. (2008) investigated off-target effects and found four potential non-T-channel effects: σ-receptor blockade, sodium channel site 2 binding, slight inhibition of Ca V 2.2 and hERG potassium channel binding. However, these effects were variable across assays, and warrant further investigation. Additionally, Choe et al. (2011) demonstrated a slight inhibition of Ca V 2.3 currents in HEK cells at doses of 10 μM.
The high dose of TTA-P2 utilized in the current set of experiments resulted in observed behavioral depression in treated mice, which might suggest that clinical utility of TTA-P2 is limited to Table 1 . Summary of seizure and mortality experiments. Pretreatment with TTA-P2 had a significant protective effect on overall alcoholwithdrawal/chemoconvulsant-induced mortality, latency to seizure and latency to death TTA-P2 SAL 10 mg/kg 20 mg/kg 40 mg/kg n = 10 n = 8 n = 12 n = 11
Seizure mortality* (died/total) 9/10 (90%) 6/8 (75%) 6/12 (50%) 3/11 (27%) Latency to seizure (mean ± SEM) 139.7 ± 22.12 407.8 ± 175.5 1033 ± 376.8* 2842 ± 362.9*** Latency to death (mean ± SEM) 999.2 ± 308.2 1369 ± 526.8 2213 ± 435.6* 3313 ± 258.7** *Significantly different (Chi-square, P < 0.05). **Significantly different (ANOVA, P < 0.001). ***Significantly different (ANOVA, P < 0.0001). lower doses. Indeed, Shipe et al. (2008) noted that there were no behavioral disturbances in conscious dogs perfused with steady TTA-P2 (1.29 mg/kg for 1 h, and then 4.3 mg/kg for a second hour), nor were there changes in heart rate, arterial blood flow, ECG intervals. Higher doses (20 mg/kg) retained renal function but did induce slight panting and increased heart rate. Additionally, 1 μM TTA-P2 blocked the induction of LTP in the cerebellum of wild-type mice (Ly et al., 2013) , which could suggest that some forms of learning may be affected by this drug. More research is needed to determine the safety of TTA-P2 for use in humans in realistic clinical scenarios. T-channels, unlike L-, N-, P/Q and R-type Ca 2+ channels, are low-voltage Ca 2+ channels (Perez-Reyes, 2003) . Upon activation, calcium is permitted entry into the cell as the channel generates Tcurrent. This low-threshold Ca 2+ spike can generate bursts of action potentials. T-channel activity can also switch neurons from tonic firing mode to burst firing mode, which is a property that underlies oscillatory activity, such as sleep and seizure (Crunelli et al., 1989; Huguenard and Prince, 1992; Steriade et al., 1993; McCormick and Bal, 1997; Huguenard, 1999; Perez-Reyes, 2003; Steriade, 2005) . Moreover, WD from alcohol can increase the expression of Tchannels and cause a depolarizing shift in these channels in brain areas known to contribute to the development of seizure (Walker and Zornetzer, 1974; Nordskog et al., 2006; Graef et al., 2011; Wiggins et al., 2013) . It is hypothesized that multiple WDs from alcohol have a 'kindling-like' effect on the brain, with each subsequent WD period bringing the subject closer to a WD-induced tonic-clonic seizure. Indeed, we and others have demonstrated that blocking T-channels is protective against tonic-clonic seizures (Riegle et al., 2015; Sakkaki et al., 2016) . Thus, selectively blocking T-channels may be an effective treatment for individuals undergoing alcohol WD. Further investigation is necessary to determine how alcohol interacts with T-channels, although it appears that alcohol indirectly effects these channels, probably through the actions of protein kinase C (PKC; Shan et al., 2013) . Because alcohol WDinduced hyperexcitability is progressive (Riegle et al., 2014) , early treatment will be crucial for preventing seizure episodes. 
